A team of German scientists believes the Covid-19 vaccines developed by Oxford-AstraZeneca and Johnson & Johnson (J&J) can be redesigned to avoid the rare, but potentially harmful, blood clots that have been reported in vaccinated people. The J&J and the AstraZeneca vaccines used a similar technology, known as adenoviral vectors, leading some experts to speculate there might be a link between this vaccine platform and the blood clotting condition, Dr Kylie Quinn said in an article in The Conversation. The condition is known as vaccine-induced immune thrombotic thrombocytopenia (VITT).

Source: News 24 May 28, 2021 02:15 UTC